Effect of chronic obstructive pulmonary disease combined with ventilator‑associated pneumonia on patient outcomes: A systematic review and meta‑analysis

Yin,Mingyuan; Liu,Meirong

doi:10.3892/etm.2020.9403

Effect of chronic obstructive pulmonary disease combined with ventilator‑associated pneumonia on patient outcomes: A systematic review and meta‑analysis

Authors:
- Mingyuan Yin
- Meirong Liu
View Affiliations

Affiliations: Department of Nursing, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410001, P.R. China, Department of Outpatient Administration, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410001, P.R. China
Published online on: October 27, 2020 https://doi.org/10.3892/etm.2020.9403
Article Number: 273
Copyright: © Yin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present systematic review and meta‑analysis was to uncover whether chronic obstructive pulmonary disease (COPD) as a co‑morbidity influences outcomes of patients with ventilator‑associated pneumonia (VAP) compared to VAP alone and whether the development of VAP in patients with COPD is associated with poor outcome in comparison to COPD alone. An electronic search of the PubMed, Embase, Scopus, BioMed Central, CENTRAL and Google scholar databases for all types of studies assessing the influence of COPD on outcomes of patients with VAP and vice versa was performed. A total of 7 studies were included. Of these, 3 studies assessed the impact of COPD on outcomes of patients with VAP. Meta‑analysis indicated that the presence of COPD significantly increased the mortality of patients with VAP [risk ratio (RR): 1.37, 95% CI: 1.14‑1.65, I²=3%, P=0.007]. The analysis failed to demonstrate any significant effect of COPD on the duration of mechanical ventilation in patients with VAP [mean difference (MD): 2.37, 95% CI: ‑5.77 to 10.50, I²=38%, P=0.57]. However, the duration of the intensive care unit (ICU) stay was significantly longer in patients with COPD and VAP as compared with that of patients with VAP without COPD (MD: 5.53, 95% CI: 0.73‑10.33, I²=0%, P=0.02). A total of 4 studies assessed the impact of VAP on outcomes of patients with COPD. Meta‑analysis indicated that the presence of VAP significantly increased mortality of patients with COPD (RR: 1.52, 95% CI: 1.08‑2.12, I²=71%, P=0.02). Pooled analysis indicated that the presence of VAP in patients with COPD significantly increased the duration of mechanical ventilation (MD: 13.73, 95% CI: 7.86‑19.61, I²=92%, P<0.00001) and the duration of the ICU stay as compared to patients with COPD but without VAP (MD: 17.36, 95% CI: 9.55‑25.17, I²=90%, P<0.0001). To conclude, within the limitations of the study, the present results indicated that the combination of COPD and VAP significantly increased patient mortality and the duration of ICU stay. The development of VAP in patients with COPD also significantly increased the duration of mechanical ventilation. Further case‑matched studies are required to assess the influence of the severity of COPD in combination with VAP on patient outcomes.

View Figures

View References

1	Rouzé A, Boddaert P, Martin-loeches I, Povoa P, Rodriguez A, Ramdane N, Salluh J, Houard M and Nseir S: Impact of chronic obstructive pulmonary disease on incidence, microbiology and outcome of ventilator-associated lower respiratory tract infections. Microorganisms. 8(165)2020.PubMed/NCBI View Article : Google Scholar
2	Tsiligianni I, Metting E, Van Der Molen T, Chavannes N and Kocks J: Morning and night symptoms in primary care COPD patients: A cross-sectional and longitudinal study. An UNLOCK study from the IPCRG. NPJ Prim Care Respir Med. 26(16040)2016.PubMed/NCBI View Article : Google Scholar
3	Tantucci C and Pini L: Inhaled corticosteroids in COPD: Trying to make a long story short. Int J Chron Obstruct Pulmon Dis. 15:821–829. 2020.PubMed/NCBI View Article : Google Scholar
4	Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 176:532–555. 2007.PubMed/NCBI View Article : Google Scholar
5	Kallet RH: Ventilator bundles in transition: From prevention of ventilator-associated pneumonia to prevention of ventilator-associated events. Respir Care. 64:994–1006. 2019.PubMed/NCBI View Article : Google Scholar
6	Hellyer TP, Ewan V, Wilson P and Simpson AJ: The Intensive Care Society recommended bundle of interventions for the prevention of ventilator-associated pneumonia. J Intensive Care Soc. 17:238–243. 2016.PubMed/NCBI View Article : Google Scholar
7	Koulenti D, Parisella FR, Xu E, Lipman J and Rello J: The relationship between ventilator-associated pneumonia and chronic obstructive pulmonary disease: what is the current evidence? Eur J Clin Microbiol Infect Dis. 38:637–647. 2019.PubMed/NCBI View Article : Google Scholar
8	Moher D, Liberati A, Tetzlaff J and Altman DG: PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 6(e1000097)2009.PubMed/NCBI View Article : Google Scholar
9	Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, Jang BH and Son HJ: Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 66:408–14. 2013.PubMed/NCBI View Article : Google Scholar
10	Wan X, Wang W, Liu J and Tong T: Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile. range. 14(135)2014.PubMed/NCBI View Article : Google Scholar
11	Nseir S, Di Pompeo C, Soubrier S, Cavestri B, Jozefowicz E, Saulnier F and Durocher A: Impact of ventilator-associated pneumonia on outcome in patients with COPD. Chest. 128:1650–1656. 2005.PubMed/NCBI View Article : Google Scholar
12	Koulenti D, Blot S, Dulhunty JM, Papazian L, Martin-Loeches I, Dimopoulos G, Brun-Buisson C, Nauwynck M, Putensen C, Sole-Violan J, et al: COPD patients with ventilator-associated pneumonia: Implications for management. Eur J Clin Microbiol Infect Dis. 34:2403–2411. 2015.PubMed/NCBI View Article : Google Scholar
13	Badawy MS, Omar HM, Mohamdien HA, Moktar EA and Deaf EA: Evaluation of risk factors of ventilator associated pneumonia on outcome of acute exacerbation of chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc. 64:799–803. 2015.
14	Hadda V, Khilnani GC, Dubey G, Nallan R, Kumar G and Guleria R: Impact of ventilator associated pneumonia on outcome in patients with chronic obstructive pulmonary disease exacerbation. Lung India. 31:4–8. 2014.PubMed/NCBI View Article : Google Scholar
15	Rinaudo M, Ferrer M, Terraneo S, De Rosa F, Peralta R, Fernández-Barat L, Li Bassi G and Torres A: Impact of COPD in the outcome of ICU-Acquired pneumonia with and without previous intubation. Chest. 147:1530–1538. 2015.PubMed/NCBI View Article : Google Scholar
16	Makris D, Desrousseaux B, Zakynthinos E, Durocher A and Nseir S: The impact of COPD on ICU mortality in patients with ventilator-associated pneumonia. Respir Med. 105:1022–1029. 2011.PubMed/NCBI View Article : Google Scholar
17	Celli BR and MacNee W: ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J. 23:932–946. 2004.PubMed/NCBI View Article : Google Scholar
18	Wu D, Wu C, Zhang S and Zhong Y: Risk factors of ventilator-associated pneumonia in critically III patients. Front Pharmacol. 10(482)2019.PubMed/NCBI View Article : Google Scholar
19	van der Kooi TII, Boshuizen H, Wille JC, de Greeff SC, van Dissel JT, Schoffelen AF and van Gaalen RD: Using flexible methods to determine risk factors for ventilator-associated pneumonia in the Netherlands. PLoS One. 14(e0218372)2019.PubMed/NCBI View Article : Google Scholar
20	Rello J, Ausina V, Ricart M, Castella J and Prats G: Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest. 104:1230–1235. 1993.PubMed/NCBI View Article : Google Scholar
21	Torres A, Aznar R, Gatell JM, Jiménez P, González J, Ferrer A, Celis R and Rodriguez-Roisin R: Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis. 142:523–528. 1990.PubMed/NCBI View Article : Google Scholar
22	Ranzani OT, Ferrer M, Esperatti M, Giunta V, Bassi GL, Carvalho CR and Torres A: Association between systemic corticosteroids and outcomes of intensive care unit-acquired pneumonia. Crit Care Med. 40:2552–2561. 2012.PubMed/NCBI View Article : Google Scholar
23	Scott A, Wang X, Road J and Reid W: Increased injury and intramuscular collagen of the diaphragm in COPD: Autopsy observations. Eur Respir J. 27:51–59. 2006.PubMed/NCBI View Article : Google Scholar
24	Rodríguez A, Lisboa T, Solé-Violán J, Gómez F, Roca O, Trefler S, Gea J, Masclans JR and Rello J: Impact of nonexacerbated COPD on mortality in critically Ill patients. Chest. 139:1354–1360. 2011.PubMed/NCBI View Article : Google Scholar
25	Moghoofei M, Azimzadeh Jamalkandi S, Moein M, Salimian J and Ahmadi A: Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis. Infection. 48:19–35. 2020.PubMed/NCBI View Article : Google Scholar
26	Wu VKS, Fong C, Walters AM and Lele AV: Prevalence, clinical characteristics, and outcomes related to ventilator-associated events in neurocritically Ill patients. Neurocrit Care. 33:499–507. 2020.PubMed/NCBI View Article : Google Scholar
27	Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, Hanisch EW, Klarin B, Koeman M, Krueger WA, et al: Attributable mortality of ventilator-associated pneumonia: A meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 13:665–671. 2013.PubMed/NCBI View Article : Google Scholar
28	Kong CW and Wilkinson TM: Predicting and preventing hospital readmission for exacerbations of COPD. ERJ Open Res. 6:00325–02019. 2020.PubMed/NCBI View Article : Google Scholar
29	Balasubramanian P and Tullu MS: Study of ventilator-associated pneumonia in a pediatric intensive care Unit. Indian J Pediatr. 81:1182–1186. 2014.PubMed/NCBI View Article : Google Scholar
30	Karakuzu Z, Iscimen R, Akalin H, Girgin NK, Kahveci F and Sinirtas M: Prognostic risk factors in ventilator-associated pneumonia. Med Sci Monit. 24:1321–1328. 2018.PubMed/NCBI View Article : Google Scholar
31	Ranjan N, Chaudhary U, Chaudhry D and Ranjan KP: Ventilator-associated pneumonia in a tertiary care intensive care unit: Analysis of incidence, risk factors and mortality. Indian J Crit Care Med. 18:200–204. 2014.PubMed/NCBI View Article : Google Scholar
32	Crisafulli E, Barbeta E, Ielpo A and Torres A: Management of severe acute exacerbations of COPD: An updated narrative review. Multidiscip Respir Med. 13(36)2018.PubMed/NCBI View Article : Google Scholar
33	Singanayagam A, Schembri S and Chalmers JD: Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis. Ann Am Thorac Soc. 10:81–89. 2013.PubMed/NCBI View Article : Google Scholar
34	Recio Iglesias J, Díez-Manglano J, López García F, Díaz Peromingo JA, Almagro P and Varela Aguilar JM: Management of the COPD patient with comorbidities: An experts recommendation document. Int J Chron Obstruct Pulmon Dis. 15:1015–1037. 2020.PubMed/NCBI View Article : Google Scholar
35	Crawley A, Laubscher T, Muddiman P and Kosar L: Pharmacologic management of COPD: Breadth of products for encouraging a breath of air. Can Fam Physician. 62:410–414. 2016.PubMed/NCBI
36	Yamauchi Y, Yasunaga H, Hasegawa W, Sakamoto Y, Takeshima H, Jo T, Matsui H, Fushimi K and Nagase T: Effect of outpatient therapy with inhaled corticosteroids on decreasing in-hospital mortality from pneumonia in patients with COPD. Int J Chron Obstruct Pulmon Dis. 11:1403–1411. 2016.PubMed/NCBI View Article : Google Scholar
37	Sibila O, Soto-Gomez N and Restrepo MI: The risk and outcomes of pneumonia in patients on inhaled corticosteroids. Pulm Pharmacol Ther. 32:130–136. 2015.PubMed/NCBI View Article : Google Scholar